This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Yvonne J. Bryson, MD
UCLA School of Medicine Los Angeles, Calif

JAMA. 1995;273(5):377.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Sarkar points out that multivariate analysis of the potential factors associated with maternal-fetal transmission would be preferable to a univariate analysis. We agree. However, because of the small sample size of our cohort and the large number of variables, this was not possible and would have added nothing to our results. We hope that as our cohort size increases this will become possible.

We analyzed all of the factors outlined in Table 2 of the original article stratified for zidovudine use. As discussed in the article, we found that the observations of increased transmission risk, associated both with exposure to maternal blood and with the presence of maternal p24 antigemia, were even more significant in the zidovudine-untreated mothers. The problem of dealing with the analysis of results based on infant outcome in multiple pregnancies and twins is difficult, but we based our assumptions on the fact that . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?